Scientific Online Resource System

Annual for Hospital Pharmacy

Current pharmacotherapy of uterine leiomyomas

Vesela Karamisheva

Abstract

Uterine leiomyomas are the most common benign tumors in women. The main symptoms include abnormal uterine bleeding, dysmenorrhea, pelvic pain and infertility. Between 25 and 50% of patients with leiomyomas undergo surgical treatment - hysterectomy or myomectomy. In recent years, more ways for pharmacologic treatment of these tumors are being sought. The classic drugs to control fibroids are progestins and combined estrogen-progestin drugs. Significant advances in the treatment of uterine leiomyomas have been the use of gonadotropin-releasing hormone agonists and antagonists, as well as selective progesterone receptor modulators. There are many studies proving their effectiveness. This review brings together information on all therapies currently used to control the disease.

Keywords

pharmacotherapy, uterine leiomyomas

Full Text


References

Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American journal of obstetrics and gynecology. 2003;188(1):100-7.

Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best practice & research Clinical obstetrics & gynaecology. 2008;22(4):571-88.

Barjon K, Mikhail LN. Uterine Leiomyomata. StatPearls. Treasure Island (FL)2020.

Benassayag C, Leroy MJ, Rigourd V, Robert B, Honoré JC, Mignot TM, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. The American journal of physiology. 1999;276(6):E1112-8.

Spasova V, Karamisheva V, Nachev A, Koleva L, Todorov Y, Toncheva D. Clinical case - giant uterine leiomyoma, mimicking an ovarian cancer. Redki bolesti i lekarstva siraci. 2019;10(4):5-7.

Maheux R. Treatment of uterine leiomyomata: past, present and future. Hormone research. 1989;32 Suppl 1:125-33.

Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157-78.

El-Balat A, DeWilde RL, Schmeil I, Tahmasbi-Rad M, Bogdanyova S, Fathi A, et al. Modern Myoma Treatment in the Last 20 Years: A Review of the Literature. Biomed Res Int. 2018;2018:4593875-.

Sohn GS, Cho S, Kim YM, Cho CH, Kim MR, Lee SR. Current medical treatment of uterine fibroids. Obstetrics & gynecology science. 2018;61(2):192-201.

Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. The Cochrane database of systematic reviews. 2013(1):Cd000400.

Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstetrics and gynecology. 1986;68(1):10-2.

Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta obstetrician et gynecologica Scandinavica. 2012;91(5):529-37.

Ip PP, Lam KW, Cheung CL, Yeung MC, Pun TC, Chan QK, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. The American journal of surgical pathology. 2007;31(8):1215-24.

Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed Res Int. 2018;2018:2414609.

Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Archives of gynecology and obstetrics. 2013;288(1):139-48.

Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157-78.

Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. British medical journal (Clinical research ed). 1986;293(6543):359-62.

Samadi AR, Lee NC, Flanders WD, Boring JR, 3rd, Parris EB. Risk factors for self-reported uterine fibroids: a case-control study. American journal of public health. 1996;86(6):858-62.

Ortmann O, Weiss JM, Diedrich K. Gonadotrophinreleasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reproductive biomedicine online. 2002;5 Suppl 1:1-7.

Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun JL, De Jesus I, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. European journal of obstetrics, gynecology, and reproductive biology. 2012;165(2):156-64.

ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstetrics and gynecology. 2008;112(2 Pt 1):387-400.

Harrison-Woolrych M, Robinson R. Fibroid growth in response to high-dose progestogen. Fertility and sterility. 1995;64(1):191-2.

Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2004;24(7):798-800.

Hoffman BL, Williams JW. Williams gynecology: Univerza v Ljubljani, Medicinska fakulteta; 2012.

Xu Q, Ohara N, Liu J, Amano M, Sitruk-Ware R, Yoshida S, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Molecular human reproduction. 2008;14(3):181-91.

Moroni R, Vieira C, Ferriani R, Candido-Dos-Reis F, Brito L. Pharmacological treatment of uterine fibroids. Annals of medical and health sciences research. 2014;4(Suppl 3):S185-92.

Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertility and sterility. 2003;79(3):628-31.

Hilário SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertility and sterility. 2009;91(1):240-3.

Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertility and sterility. 2010;93(1):192-8.

ACOG Practice Bulletin No. 96: Alternatives to Hysterectomy in the Management of Leiomyomas. Obstetrics & Gynecology. 2008;112(2 Part 1):387-400.

Spasova V, Karamisheva V, Staneva R, Hadjidekova S, Antonova O, Koleva L, Tonchev D. Endometriosis – review of current therapeutic appraches for disease control. Annual for Hospital Pharmacy. 2019;5(1):27-37.

Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Current opinion in obstetrics & gynecology. 2004;16(3):239-43.

Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. The Cochrane database of systematic reviews. 2001(2):Cd000547.

Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebocontrolled, multicenter study. The Leuprolide Study Group. Obstetrics and gynecology. 1991;77(5):720-5.

ACoP B-G. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstetrics and gynecology. 2006;107(6):1453-72.

Engel JB, Audebert A, Frydman R, Zivny J, Diedrich K. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. European journal of obstetrics, gynecology, and reproductive biology. 2007;134(2):225-32.

Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertility and sterility. 2007;87(6):1399-412.




DOI: http://dx.doi.org/10.14748/ahp.v7i1.8071

Refbacks

Article Tools
Email this article (Login required)
|